This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Shaul G. Massry, MD

JAMA. 1995;273(21):1693-1695.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Three major clinical trials that dealt with approaches to retard the progression of chronic renal failure have been completed.^1-3 The first two examined whether therapy with angiotensin-converting enzyme (ACE) inhibitors, captopril,¹ or intensive treatment with insulin² ameliorates the progression of renal failure in patients with insulin-dependent diabetes mellitus (IDDM). It was found that captopril given in dosages of 25 mg three times daily for 1.8 to 4.8 years (median, 3.0 years) reduced the doubling of serum creatinine levels by 48% in patients with IDDM who had an initial serum creatinine concentration below 220 µmol/L (<2.5 mg/dL) compared with those receiving placebo; therapy with captopril was more effective than blood pressure control alone.¹ The Diabetes Control and Complication Trial demonstrated that intensive insulin therapy to control blood glucose levels close to normal values in patients with IDDM delays the onset and slows the progression of diabetic nephropathy, . . . [Full Text PDF of this Article]

Author Affiliations
University of Southern California School of Medicine, Los Angeles

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?